• Explore /
  • Poster
  • / Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Abstract Poster

Authors

null

Shukui Qin

Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China

Shukui Qin , Weijia Fang , ZhengGang Ren , Ou Shuangyan , Ho Yeong Lim , Feng Zhang , Hye Jin Choi , Jiandong Tong , Min Tao , Aibing Xu , Ashley Chi Kin Cheng , Chang-Hsien Lu , Chang-Fang Chiu , Mohamed Ibrahim A. Wahid , Shital Kamble , Josephine M. Norquist , Wen Yan Zhong , Chen Li , Zhendong Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03062358

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4088)

DOI

10.1200/JCO.2022.40.16_suppl.4088

Abstract #

4088

Poster Bd #

75

Abstract Disclosures

Similar Posters

First Author: Shukui Qin

First Author: Richard S. Finn

First Author: Masatoshi Kudo

First Author: Josep M Llovet